Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Welcome and Introduction to Vi3C

Deborah Collyar: What's In It for Patients?

Cost of Care

Health-Care Policy

The ASCO Post Staff

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Blase N. Polite, MD, MPP, of the University of Chicago Medical Center, discusses his belief that, in the next few years, we can bend the cancer drug cost curve and tame health-care costs if physicians, pharmaceutical companies, payers, and government come together and agree on the value of treatments that improve survival and quality of life.

Jan

Today In Oncology

Opening Session Panel Discussion

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Welcome and Introduction to Vi3C

Deborah Collyar: What's In It for Patients?

Blase N. Polite, MD, MPP, on Optimizing Cancer Policies in the United States

Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides

HCC LLM Advice and Treatment Concordance

Can a Genetic Variant Affect the Efficacy of Abiraterone

Breast Cancer Risk May Be Linked to Physical Activity Levels in Adolescence

What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?